Pharmaceutical Product Monograph: Enoxaparin Sodium (80 mg / 0.8 mL)
In the pharmaceutical industry, Enoxaparin is a Low Molecular Weight Heparin (LMWH). As a pharmacist and manufacturer, I view this molecule as a “Precision Anticoagulant”—it is technically designed by the depolymerization of porcine mucosal heparin to create a predictable, weight-based response with a higher ratio of Anti-Factor Xa to Anti-Factor IIa activity than standard heparin.
At your WHO-GMP facility in Mumbai, Enoxaparin 80 mg is a high-value, critical care SKU. The 80 mg (8,000 IU) dose is specifically a therapeutic dose, typically reserved for treating active clots rather than just preventing them.
Therapeutic Profile: Primary Indications
Enoxaparin 80 mg is indicated for the treatment of established thromboembolic diseases and acute coronary syndromes.
| Indication | Clinical Context | Technical Rationale |
| DVT Treatment | Deep Vein Thrombosis | Used to treat existing clots in the deep veins (usually legs) to prevent them from traveling to the lungs. |
| Pulmonary Embolism | PE Management | First-line therapy for stable patients with a blood clot in the lung. |
| Unstable Angina / NSTEMI | Cardiology | Administered alongside Aspirin to prevent complete blockage of the coronary arteries during a “minor” heart attack. |
| STEMI | Acute Heart Attack | Used in combination with thrombolytics (clot-busters) to maintain vessel openness after an emergency procedure. |
| Bridging Therapy | Pre-Surgery | Used for patients on Warfarin who need to stop their oral meds for surgery but remain at high risk for clots. |
Mechanism: The Factor Xa Inhibition
Enoxaparin works by accelerating the body’s natural “brake” on blood clotting:
Antithrombin III Binding: Enoxaparin binds to a plasma protein called Antithrombin III.
Specific Inhibition: This complex specifically neutralizes Factor Xa (and to a lesser extent, Factor IIa/Thrombin).
Clot Prevention: By blocking Factor Xa, the “Coagulation Cascade” is interrupted, preventing the conversion of prothrombin to thrombin and the subsequent formation of a fibrin clot.
Predictability: Technically, because the molecules are smaller (Low Molecular Weight), the drug does not bind to as many “distractor” proteins in the blood, leading to a highly predictable dose-response.
The Pharmacist’s “Technical Warning”
The “Epidural” Black Box: As a pharmacist, I must emphasize the most critical safety warning: patients receiving spinal anesthesia or an epidural while on Enoxaparin are at risk of a Spinal Hematoma, which can cause permanent paralysis.
Injection Technique: This is a Subcutaneous (SC) injection, typically given in the “love handles” of the abdomen. Do not expel the nitrogen bubble from the pre-filled syringe; it is technically designed to “seal” the drug into the tissue and prevent bruising.
Renal Clearance: Enoxaparin is cleared by the kidneys. For patients with severe renal impairment ($CrCl < 30 \text{ mL/min}$), the 80 mg dose is technically dangerous and must be reduced.
Monitoring: Unlike standard Heparin, you do not monitor aPTT. If monitoring is required (e.g., in pregnancy or obesity), the Anti-Factor Xa assay is the technical gold standard.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Pre-Filled Syringe” (PFS) USP: On your digital platforms, highlight your Automated PFS Filling and Assembly. In 2026, the global B2B market prefers PFS over vials because it eliminates dosing errors and reduces the risk of needle-stick injuries for healthcare workers.
The “Anti-Factor Xa” Quality Control: Your B2B marketing should emphasize that your batch-to-batch potency is verified via chromogenic assays to meet USP/EP standards. Consistency in the 100 IU/mg activity is the technical benchmark for export.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Enoxaparin 20 mg, 40 mg, 60 mg, and 80 mg to support your registration in international B2B tenders for cardiology and orthopedics.